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The cytotoxic T-lymphocyte (CTL) response to HTLV-1 is directed mainly against the Tax protein. Circulating, activated
Tax-specific CTL can be found in a majority of healthy carriers and patients with the HTLV-1-associated disease tropical
spastic paraparesis (HAM/TSP). In this study we present data on the Tax-specific CTL response of 26 HTLV-1 carriers,
including 10 newly recruited subjects. Rex-specific CTL were not found in any subjects investigated. Activated and memory
CTL responses were determined separately in 4 healthy carriers, 3 HAM/TSP patients, and 1 ‘‘seronegative HAM/TSP.’’ In
all subjects, the mean frequency of peptide-specific memory cells per epitope (1/1307) was high. There was no significant
difference in mean memory CTL frequency per epitope or in the proportion of subjects with activated CTL between healthy
carriers and HAM/TSP patients. One individual with HAM/TSP had an unusually high frequency response to two peptides,
suggesting immunodominance of epitope recognition in this individual. We conclude that the magnitude and components
of the HTLV-1-specific CTL response do not differ between healthy carriers and HAM/TSP patients. These data do not
support a specific CTL-mediated component in the pathogenesis of HAM/TSP. q 1996 Academic Press, Inc.
INTRODUCTION viduals and represents by far the most important target of
CTL recognition in HTLV-1-infected individuals (Parker et
Class I MHC-restricted cytotoxic T-cells (CTL) are po-
al., 1994). Tax is a regulatory protein which indirectly con-
tent anti-viral effectors in vitro and in vivo (Koup, 1994).
trols viral transcription via sequences in the viral long termi-
CD8/ CTL are frequently found in the peripheral blood
nal repeat. Tax also induces the expression of several cellu-
of people infected with human T-cell leukemia virus type
lar proteins including cellular adhesion molecules. Several
1 (HTLV-1) (Jacobson et al., 1990; Parker et al., 1992).
regions within Tax can be recognized by CTL simultane-
The CTL predominantly recognize epitopes in the Tax
ously (Parker et al., 1994) and there is evidence that certain
protein of HTLV-1 and in other viral proteins to a lesser
epitopes are immunodominant.
extent (Parker et al., 1994; Furukawa et al., 1994).
Rex is the other major viral regulatory protein of HTLV-
The role (if any) of these immune cells in the pathogen-
1: it is expressed from the same mRNA as Tax but in a
esis of HTLV-1-associated diseases is not understood.
different translational open reading frame. Rex also controls
Elovaara et al. (1993) measured the precursor frequen-
the expression of viral proteins by favoring translation from
cies of peripheral blood CTL and CSF-derived CTL in
unspliced or singly spliced mRNAs and is thought to shuttle
asymptomatic carriers and HAM/TSP patients. In periph-
mRNA from the nucleus into the cytoplasm for translation
eral blood lymphocytes, they reported a precursor fre-
to occur (Adachi et al., 1993). There is no evidence of
quency of Tax-specific CTL at least 40-fold higher in
chronic Rex protein expression in HTLV-1 infection and a
HAM/TSP patients than in asymptomatic HTLV-1 carriers
CTL response to Rex has not been described.
and suggested that the presence of HTLV-1-specific CTL
The two principal aims of the present study were (1)
might contribute to the pathogenesis of HAM/TSP. We
to compare the activated and memory CTL responses to
have found strong fresh CTL responses in asymptomatic
HTLV-1 peptides in the peripheral blood CD8/ T-cells
HTLV-1-infected individuals as well as in HAM/TSP pa-
between healthy carriers and HAM/TSP patients and (2)
tients (Parker et al., 1992, 1994), and to date we have
to look for a CTL response to Rex in both freshly isolated
been unable to identify a qualitative or quantitative differ-
and cultured T-cells.
ence in these responses between patient groups.
MATERIALS AND METHODSThe Tax protein is persistently expressed in infected indi-
Subjects. A total of 14 HTLV-1-seropositive, asymptom-
atic patients were investigated. Eight of these patients1 To whom reprint requests should be addressed. Fax: 1865 222502.
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have been described elsewhere (Parker et al., 1992, lines, unfractionated PBL were cultured with the addition
of 200 mM pools of 3–10 peptides on Day 1, and cells1994), and 6 were newly recruited. In addition, 9 seropos-
itive HAM/TSP patients were included in the study (5 were fed with Lymphocult-T as before. This reduced the
peptide concentration to 50 mM over 7–10 days. Thesehave been described previously (Parker et al., 1992,
1994), 4 were newly recruited). Subject TZ is a 51-year- peptide-stimulated cultures were tested for CTL activity
after 10–14 days of stimulation. This method has beenold male born in St. Lucia who developed HAM/TSP and
uveitis within the past 2 years. He was treated with 500 shown to restimulate CTL memory cell responses in HIV-
1 patients (Klenerman et al., 1994) and HTLV-1 patientsmg azidothymidine twice daily and 3 million units of inter-
feron-alpha by subcutaneous injection daily for 6 weeks. (S. Hall and C. Bangham, unpublished data).
Limiting dilution assays. Freshly selected CD8/ lym-Three blood samples from TZ were tested; the first during
this treatment and the second and third, 4 days and 1 phocytes were plated into 96-well plates at 200, 500,
1000, and 2500 cells per well, in 30 replicate wells formonth after its discontinuation, respectively. Patients
TAA and TW were undergoing treatment with 200 mg each cell input number. Autologous, irradiated CD8-de-
pleted peripheral blood mononuclear ‘‘feeder’’ cells (105)danazol (an anabolic steroid) three times daily at the time
of being tested. Two patients with a clinical presentation were added to each well. Three days later, cells were
fed with 1 mg/ml PHA in RPMI/10% FCS/10% Lymphocult-consistent with HAM/TSP, but who are seronegative for
HTLV-1, were also investigated. A third seronegative T. After approximately 10 days, cultures were split into
replicate plates and fed with RPMI/10% FCS/10%HAM/TSP patient has been described in detail before
(Daenke et al., 1994). In the subject codes, the prefix T Lymphocult-T. Chromium release assays were done us-
ing 3000 peptide-pulsed or untreated chromium-labeledrefers to the presence of HAM/TSP, and H denotes a
healthy carrier. The MHC class I allotype was determined autologous targets per well on Days 14–25 of culture.
Frequency analysis was done by counting the numberfor each patient by polymerase chain reaction (Krausa
et al., 1993) and, in some cases, by complement-medi- of replicate wells at each cell input number that showed
specific cytotoxic lysis of target cells. The criterion ofated lysis using allospecific antisera.
CTL assays. CTL assays were standard 5-hr 51Cr-re- positivity in each assay was determined by calculating
the mean specific lysis of the 30 replicates assayed onlease assays as described (Parker et al., 1992). CD8/
effector cells were isolated freshly from PBL by positive targets without peptide preincubation, /3 standard devi-
ations of the mean. The least squares regression lineselection on M-450 anti-CD8-coated Dynabeads (Dynal).
Following selection, beads were removed from the cells was used to calculate a precursor frequency using the
method of Lefkovits and Waldmann (1979). Frequenciesby incubation with anti-sheep IgG (Detachabead, Dynal).
In fresh assays, unstimulated CD8/ cells were tested are expressed as a fraction of CD8/ cells isolated from
peripheral blood.within 24 hr of venesection. HTLV-1-specific lysis was
determined using a one-tailed t test (P 0.05) comparing Peptides. 15-Mer peptides spanning the entire protein
sequences of Tax and Rex and overlapping by five aminopeptide-pulsed or vaccinia-infected target cells with un-
treated target cells or targets pulsed with an irrelevant acids were synthesised by F-moc chemistry. Peptides
were grouped into pools of 10 for screening, and later 4,peptide.
Autologous EBV-transformed B-cell lines were used 3, or 2 peptides were pooled for mapping new epitopes. A
peptide epitope from HTLV-1 reverse transcriptase (PC4)as target cells in cytotoxic T-cell assays. Targets were
labeled with chromium and prepulsed with 50 mM pep- has been described before (Parker et al., 1992).
tide before being added to the effector cells. The concen-
tration of 50 mM peptide was used in these assays in RESULTS
order that each peptide of a pool would not be limiting.
CTL epitopes in Tax are evenly distributed throughout
Where single peptides are used to pulse target cells, this
the protein
concentration can be reduced to 0.5 mM (data not
shown). This method of target preparation has been de- In previous work (Parker et al., 1994) we identified nine
CTL peptide epitopes in Tax, all of which map to the N-scribed in detail elsewhere (Parker et al., 1994). Percent-
age specific lysis was calculated as 100 1 [(test cpm 0 terminal half of the protein. We have extended this work
by testing CTL responses in 10 newly acquired subjectsbackground cpm)/(maximal cpm 0 background cpm)].
CTL lines. T-cell lines were established in vitro without and in several subjects who have been tested previously.
In all cases, CD8/ lymphocytes derived from these sub-the addition of exogenous antigen, using CD8/ cells cul-
tured with equal numbers of autologous irradiated CD8- jects were tested for responses against a number of
peptide pools spanning the whole of the Tax or Rex pro-depleted feeder cells. Lines were expanded with 1 mg/
ml phytohaemagglutinin (PHA) and 10% Lymphocult-T teins. We (Parker et al., 1992, 1994) and others (Jacobson
et al., 1990; Furukawa et al., 1994) have found Tax to be(Biotest Diagnostics) in RPMI 1640/10% fetal calf serum
(FCS) and maintained for several weeks in RPMI/10% highly immunodominant as a CTL target antigen. In this
study using peptide pools, we were able to identify upFCS/10% Lymphocult-T. For antigen-stimulated T-cell
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FIG. 1. The full-length HTLV-1 Tax amino acid sequence is shown. Numbered bars above the sequence represent peptides recognized by CTL
from HTLV-1-infected patients. Boxed bar numbers denote newly identified Tax epitopes. The reference name (as appears in the text) of each
peptide and the HLA restriction element for recognition by CTL (where identified) is shown in the accompanying table. Subjects shown to respond
to each peptide in fresh assays or in T-cell lines are indicated. Subjects HS, HT, HW, HX, HY, HZ, TAA, TV, TW, TX, TY, and TZ are patients newly
recruited for this study.
to eight new CTL epitopes in Tax (Fig. 1). For most of targets was confirmed using endogenously presented
Tax protein expressed from pX-recombinant vaccinia vi-these epitopes, the HLA restriction allele has been identi-
fied (Fig. 1) using target B-cell lines matched and mis- rus infected target cells (data not shown; Parker et al.,
1992).matched at the HLA-A and HLA-B loci. The complete
panel of Tax epitopes are spread throughout the protein
sequence including the C-terminal end and are not clus- HTLV-1 carriers with and without HAM/TSP have
tered in the N-terminal half of the protein. In those cases activated CTL to Tax
where CTL responses to overlapping 15-mer peptides
have been identified, effector frequency data show that The data in Table 1 show CTL responses to Tax in
individuals from each of two clinical groups. Of 14 sero-these are in fact separate epitopes with different effector
frequencies, although some are presented by the same positive healthy carriers studied, 10 had a fresh CTL
response to Tax; in every case anti-Tax CTL were alsoMHC class I molecule (compare peptides X19, X20; Table
3). These data are therefore not consistent with a single found in a T-cell line derived from the CD8/ cell popula-
tion. Four of the healthy subjects did not produce a freshepitope spanning the adjacent 15-residue peptides.
While 15-mer peptides may be recognized with lower response in vitro (HC, HG, HS, HX). Two of these were
also negative when tested as a CD8/ T-cell line (HC,efficiency compared with shorter ‘‘optimized’’ peptides,
our experience has been that, following clonal expansion HX), but HS was shown to recognize peptide XN11 after
culture. A T-cell line was not established from HG.in the limiting dilution assay, very few wells give marginal
positive or negative cytolytic values. In addition, the mag- In the HAM/TSP clinical group, of nine HTLV-1 sero-
positive HAM/TSP patients tested, five had a fresh re-nitude of positivity does not alter the calculation of ef-
fector frequency (Lefkovits and Waldmann, 1979). We are sponse to Tax, four failed to recognize peptide-pulsed
targets in a fresh assay (Table 1). In all of these patientsconfident that 15-mer peptides accurately estimate, if not
closely underestimate, the effector frequencies of CTL. In except TB, HTLV-1 peptides were specifically recognized
by their respective cultured T-cell lines. The proportionall cases, Tax-specific lysis identified on peptide-pulsed
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TABLE 1
Tax-Specific CTL Responses in HTLV-1-Infected Subjects
Healthy subjects Tax response TSP subjects Tax response
Subject code Antibody Fresh T-cell line Subject code Antibody Fresh T-cell line
HA / / / TB / / nd
HB / / / TD / / /
HD / / / TE / / /
HH / / / TF / / /
HM / / / TZ / / /
HN / / / .(5)
HT / / /
HW / / / TAA / Negative /
HY / / / TI / Negative /
HZ / / / TV / Negative /
.(10) TW / Negative /
.(4)
HC / Negative Negative
HG / Negative nd TO Sero-ve Negative nd
HS / Negative / TX Sero-ve Negative Negative
HX / Negative Negative TY Sero-ve Negative Negativea
.(4) .(3)
Note. CD8/ cells from 14 healthy HTLV-1 carriers and 12 HAM/TSP patients were tested for recognition of HTLV-1 peptide antigens presented
by autologous B-cell lines in a chromium release assay. The HTLV-1-specific lysis was called positive if it significantly (P  0.05) exceeded the
lysis of untreated target cells (Student’s t test, one-tailed). A summary of these data for fresh CTL responses and T-cell line responses are shown.
The HTLV-1-specific antibody status of each subject is shown. TO, TX, and TY were seronegative for HTLV-1 but were shown to have HTLV-1
proviral sequences in the genomic DNA. These patients had a clinical presentation consistent with HAM/TSP. nd, not done.
a TY did not recognize HTLV-1 Tax or Rex peptides in a fresh assay or in a bulk T-cell line but did show reactivity to peptide TVO (see Fig. 1) in
the limiting dilution analysis.
of fresh CTL responders to Tax in the healthy carrier sponses to Tax and 2 had responses in the T-cell line
only. HW and TZ had Pol-specific CTL in addition. Subjectgroup (10/14) and the HAM/TSP group (5/9) did not differ
significantly (x2  0.821; P  0.25 at 1 df). HX was negative for a Tax-specific response but positive
for HTLV-1 antibodies (see Table 1). Cytotoxic T-cell re-Three seronegative patients in whom HTLV-1 proviral
sequences have been identified (TO (Daenke et al., sponses to Rex could not be found in any of these sub-
jects. Assays for Rex responsiveness were done using1994); TX, TY (M. Sommerlund and C. Bangham, unpub-
lished data)), and who have a clinical syndrome indistin- peptide pools in all subjects. In all fresh assays, the
effectors were tested within 12 to 24 hr of venesection,guishable from HAM/TSP, were included in the study.
No CTL could be identified in subject TO who has been as in the assays for Tax-specific CTL. Where T-cell lines
were established from the sample, these were testedshown to have a deleted provirus integrated into his ge-
nomic DNA (Daenke et al., 1994). Two newly recruited 10–15 days after antigen nonspecific (PHA and Lympho-
cult-T) or antigen-specific (Rex peptide pools) stimulationsubjects, TX and TY likewise had no fresh CTL response
to Tax peptides and no significantly detectable response in vitro. In 24 experiments, T-cell lines were tested for
reactivity to Rex peptides one to three times without pep-to Tax in the T-cell lines established from their cells.
However, in one case (TY), Tax-specific CTL were identi- tide stimulation and two to three times after peptide stim-
ulation, but were consistently negative (data not shown).fied in a limiting dilution assay after expansion of the
clones (see Table 3). This shows that weak CTL re-
sponses may not be detectable in a fresh assay of circu- Frequencies of HTLV-1 specific memory CTL are
lating cells, but HTLV-1-specific memory cells can be similar in healthy carriers and HAM/TSP patients
amplified by culture in vitro with PHA and IL-2.
Frequencies of CTL in the peripheral blood of subjects
from both clinical groups were studied by limiting dilutionRex-specific CTL were not detected in any HTLV-1
analysis. Both CD4/ and CD8/ T-cells from HTLV-1-in-infected subjects
fected subjects tend to proliferate spontaneously in vitro
(Hollsberg et al., 1992). In our analysis of these data, weFourteen subjects were investigated for fresh CTL re-
sponses to Rex (Table 2). Thirteen of these subjects had have used the term ‘‘effector frequency’’ in preference to
‘‘precursor frequency’’ because, although it is likely thatbeen found to have Tax-specific CTL; 11 had fresh re-
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TABLE 2
Rex-Specific CTL Responses in HTLV-1–Infected Subjects
Healthy subjects Rex response TSP subjects Rex response
Subject Antibody Fresh T-cell line Subject Antibody Fresh T-cell line
HA / Negative nd TAA / Negative nd
HB / Negative nd TD / Negative nd
HM / Negative Negative TV / Negative nd
HN / nd Negative TW / Negative Negative
HT / Negative Negative TZ / Negative nd
HW / nd Negative
HX / nd Negative
HY / Negative nd
HZ / Negative Negative
Note. Thirteen HTLV-1 Tax responsive patients (eight healthy; five HAM/TSP) were tested for CTL recognition of Rex peptides by fresh or cultured
CTL. Subject HX (negative for Tax-specific CTL) was also tested. No Rex-specific CTL were detected in these subjects.
the majority of this response is due to restimulated mem- In subject HM, frequencies of CTL effectors to two
separate peptide epitopes were calculated. For theseory CTL, some contribution of proliferating activated CTL
cannot be excluded. two epitopes, both of which are recognized by fresh CTL,
frequency values were similar at 1/2643 CD8/ (XN3) andLimiting dilution cultures were assayed on peptide-
pulsed autologous targets in all cases, after peptide epi- 1/1392 CD8/ cells (XN11). In subject TZ, five peptides
were tested in the limiting dilution assay. Calculated fre-topes had been identified in fresh CTL assays or T-cell
lines. This allows efficient quantification of target-specific quency values ranged from 1/223 to 1/4218 CD8/ cells
(Table 3 and Fig. 2). These data show that some peptide-effectors because it does not depend on the efficiency
of expression and processing of an endogenously pro- specific CTL are more frequent in the peripheral circula-
tion than others in this individual. The total Tax-specificduced recombinant protein. The calculated effector fre-
quencies for each peptide epitope specified are shown in CTL effector frequency (sum of the frequencies for each
epitope recognized simultaneously) in this subject wasTable 3. The mean frequency of HTLV-1 peptide-specific
effectors per epitope did not differ significantly between 1/129. The two peptides recognized by the highest fre-
quencies of CTL in the limiting dilution analysis also gavethe healthy carriers and HAM/TSP patients (Student’s t
test; t  00.964, P  0.358 at 10 df ). the highest levels of lysis in assays of freshly isolated
TABLE 3
Frequencies of HTLV-1-Specific CTL in Healthy Carriers and TSP Patients
Subject Target peptide Frequency Subject Target peptide Frequency
HM XN3 1/2643 TD PC4 1/2719
HM XN11 1/1392 TV X6 1/2618
HW X13 1/3103 TZ X2 1/3181
HZ PC4 1/3197 TZ X19 1/223
HS XN11 1/3141 TZ X20 1/4218
TZ X3 1/588
TZ X10 1/4176
Mean H freq/epitope 1/2438 Mean T freq/epitope 1/906
U1 PC4 1/94,870 TY TV0 1/5838
U2 TV0 1/56,989
Mean U freq/epitope 1/71,205
Note. Effector frequencies from limiting dilution analysis of CTL responding to known peptide epitopes were calculated according to the method
of Lefkovits and Waldmann (1979). For each epitope assayed, effector frequencies are represented as a fraction of the CD8/ lymphocyte population
(1/x, 1/y, etc.) positively selected from the peripheral blood of patients. The mean frequency values per epitope were calculated as the combined
effector frequency to several epitopes ((1/x) / (1/y) / (1/z), etc)/n. Clinical groups are defined as healthy carriers (H), HAM/TSP patients (T), and
uninfected controls (U).
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Eleven of 26 subjects (5 healthy carriers and 6 HAM/TSP
patients) respond to more than one epitope in Tax (see
Fig. 1). Fresh CTL responses were found in a similar
proportion of subjects belonging to each clinical group
as were CTL responses in T-cell lines derived from pe-
ripheral CD8/ cells. This shows that HTLV-1-infected
healthy carriers and HAM/TSP patients are equally able
to mount a CTL response to the virus and that Tax expres-
sion is persistent in most infected individuals.
HAM/TSP patients have been shown to have a higher
viral load than healthy carriers (Yoshida et al., 1989; Shin-
zato et al., 1993). Recently, however, the levels of tax
mRNA per infected cell in healthy carriers and HAM/TSP
patients has been shown to be the same (Furukawa etFIG. 2. Limiting dilution analysis of CTL from subject TZ. A semilog plot
of the fraction of 30 replicate wells of CTL responding to peptide-pulsed al., 1995). This suggests that the differences in viral load
autologous targets (y-axis) is shown as a function of the effector cell input/ and levels of viral expression between healthy and HAM/
well (x-axis). Linear regression analysis allows the calculation of effector TSP patients relate to the number of infected cells per
frequency which corresponds to the cell input number at which the fraction
patient rather than the transcriptional activity of the virus.of unresponsive wells is 0.37. The figure shows the data for lysis of peptide
This might suggest that healthy carriers have a moretargets X2, X3, X10, X19, and X20 by CTL from TZ. The frequency values
calculated from these data appear in Table 3. effective CTL response to HTLV-1 infection than HAM/
TSP patients.
Elovaara et al. (1993) found that HAM/TSP patients
CD8/ T-cells and the bulk culture of T-cells (compare
had a higher frequency of CTL responder cells circulating
Table 3 with Fig. 3). These results show that the peptides
in the peripheral blood than did healthy patients. How-
X3 and X19 were immunodominant in this subject.
ever, these data compared recognition of peptide-pulsed
A frequency of 1/5838 CD8/ Tax-specific CTL was
targets (presentation of a single epitope) with vaccinia-
measured for subject TY. This HLA-A2/, seronegative
pX-infected targets (presentation of single or multiple epi-
individual failed to show a CTL response to the HLA-A2-
topes) and are difficult to interpret. We were unable to
restricted Tax peptide 11–19 (LFGYPVYV) either in fresh
reproduce these findings in our group of subjects using
assays or in nonantigen-stimulated T-cell lines. The fre-
peptide-pulsed targets in all assays. We found no differ-
quency of effectors was lower than those seen in other
ences in the effector CTL frequencies between healthy
individuals and may have fallen below the threshold of
carriers and HAM/TSP patients, although in one individ-
sensitivity of a bulk cytotoxic lysis assay. CD8/ lympho-
ual, we showed clear immunodominance of CTL reactiv-
cytes from the peripheral blood of two uninfected volun-
ity to two Tax peptides. In this individual (TZ), the effector
teers of known HLA type were assayed on autologous
target B-cell lines pulsed with an appropriate HTLV-1-
peptide. The effector frequencies were calculated as 1/
56,989 and 1/94,870 CD8/ cells in these subjects (Table
3). Although some positive wells were found in the lim-
iting dilution assays, these did not titrate with cell input
number and were similar to the frequencies calculated
for recognition of untreated B-cell lines.
DISCUSSION
The presence of CD8/ CTL specific for HTLV-1 anti-
gens has been reported in healthy HTLV-1 carriers and
in those with HAM/TSP. These CTL are predominantly
directed to the Tax protein, but other viral gene products
are also recognized on infected cells (Jacobson et al.,
1990; Parker et al., 1992). HTLV-1-specific CTL have been FIG. 3. The frequency of TZ effectors specific for Tax peptides in the
limiting dilution analysis (see Fig. 2 and Table 3) is mirrored in thefound in the CSF and in peripheral blood (Elovaara et al.,
specific lysis of peptide pulsed targets by bulk T-cell lines. T-cell lines1993) and it has been suggested that they play a role in
were tested at 10–30 days after nonantigen stimulation in vitro onthe pathogenesis of HAM/TSP by mounting a cytolytic
peptide-treated autologous B-cell lines. Percentage specific lysis is
attack against HTLV-1-infected cells in the CNS. shown at effector:target ratios of 50:1 and 10:1 for each peptide-treated
This study extends by 10 the number of individuals in target. Error bars represent { standard error of the mean of duplicate
values.whom we have identified CD8/ anti-HTLV-1 responses.
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frequencies to several peptide epitopes were studied and LDA f  1/5838). In these subjects, therefore, an
active CTL response in fresh blood was associated withover a period of 5 months. We found that while peptide
X19 was always immunodominant, CTL effector frequen- a higher effector frequency of Tax-specific memory CTL
as measured by LDA (Fig. 3, Table 3). This contrasts withcies to other peptides fluctuated with time (data not
shown) although the range of frequency values were al- other persistent viral infections where fresh CTL can be
detected only in the acute phase of the infection.ways similar (between 1/250 to 1/4000). This suggests a
dynamic process of viral protein expression and conse- A CTL response to Rex has not been reported in HTLV-
1-infected patients. Tax and Rex are products of the samequent response of the CTL effectors, and emphasizes
the difficulty in drawing conclusions about the total CTL 2.1-kb mRNA, although it is not known whether infected
cells chronically express Rex as well as Tax. In this study,response to all epitopes at one time point. This is rein-
forced by data from subject HM, where although in recent we were unable to find specific CTL responses to Rex
peptides in patients who had strong CTL activity to thebulk cultures of CD8/ cells the response to peptide XN3
was immunodominant (data not shown) this has not al- Tax protein and in some cases to a peptide derived from
Pol. We were unable to test for recognition of endoge-ways been the case (see Parker et al., 1994). When as-
sayed by limiting dilution, the effector frequency for pep- nously produced Rex protein in these experiments and
therefore the presence of natirally processed Rex epi-tide XN3 in HM was slightly lower than that for peptide
XN11. topes cannot be excluded. However, the strategy of using
peptide pools has been very successful for identifyingThe cumulative effector frequency for all epitopes mea-
sured in TZ was very high (e.g., 1/129, Table 3). This Tax epitopes and we would not expect the requirement
for Rex peptide presentation to be unusual. These datafigure should be interpreted with caution, because (1)
subject TZ has had an unusually rapid progression of emphasize the striking difference between CTL recogni-
tion of Tax and Rex peptides, rather than the completedisease, and so lies at one extreme of the HAM/TSP
clinical spectrum; (2) we have not measured the total absence of CTL epitopes in Rex which is not proven.
They are consistent with the possibility that Rex is noteffector frequency of anti-Tax CTL in other subjects; (3)
we do not know the dynamic nature of responses in other available in the cytoplasm for presentation to CTL by
MHC class I molecules, perhaps because of sequestra-individuals. We have found that limiting dilution assay
using vaccinia recombinant-infected target cells is less tion in the nucleus or Rex instability.
The pathogenesis of HAM/TSP remains speculative.sensitive than using peptide-pulsed targets (data not
shown), possibly because of competition or antagonism There is little evidence of HTLV-1 infection of resident
cells in the CNS (Hara et al., 1994; Lehky et al., 1995)between peptides processed from the recombinant pro-
tein. and although CTL have been found in the CNS (Elovaara
et al., 1993), they were not present in a substantiallyThe CTL frequencies per epitope measured in HTLV-
1-infected patients were higher than those determined higher frequency than in the same patient’s peripheral
blood. This argues against selective migration of anti-in other virus infections (Borysiewicz et al., 1988) except
for HIV-1, where frequencies of 1/3000 to 1/30,000 pe- HTLV-1 CTL into the CNS (Bangham, 1993). If activated
T-cells migrate into the CNS irrespective of antigen spec-ripheral blood lymphocytes specific for HIV-1 p24 antigen
were reported (Gotch et al., 1990). The higher effector ificity (Wekerle et al., 1986), CNS damage could be a
result of the Tax-driven secretion, by these lymphocytes,frequencies in HIV-1 and HTLV-1 are consistent with the
presence of a CTL response in freshly isolated T cells of cytokines which are known to be neurotoxic in high
concentrations (Sawada et al., 1992). Similarly, activatedin a high proportion of patients and with persistent ex-
pression of viral proteins. T-cells might migrate into other tissues, causing a wide
spectrum of HTLV-1-associated inflammatory diseasesFresh CTL assays measure specific lysis of targets by
circulating, activated CTL in the periphery. These are (Daenke and Bangham, 1994).
In summary, we have found a strong CTL response tostimulated in vivo by newly synthesized antigens in acute
and persistent virus infections. Memory CTL, which are Tax but not Rex in the peripheral blood lymphocytes of
healthy carriers and HAM/TSP patients. Both groupsquantified by limiting dilution assay, may persist for years
after clearance of the virus (Zinkernagel et al., 1993) and show similar proportions of subjects with high or low
contribution of activated and memory CTL to Tax. As thecan be assayed only after antigen-specific restimulation.
Subjects HM, HW, HZ, TD, and TZ all had activated CTL frequency, antigen specificity and activation state of Tax-
specific CTL are the same, these data do not support an(fresh responses) and high numbers of memory CTL to
tax epitopes. Subjects HS and TV had low or no activated association between high CTL activity and the develop-
ment of HTLV-1 neurological disease.CTL (no detectable fresh response) but normal numbers
of memory CTL (T-cell line and LDA, f  1/3141 and f 
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